Cure8 research brief
The study documents shifting real-world prescribing for newly diagnosed IBD in Germany, with more biologic use and less mesalazine/thiopurine in recent years — changes that could affect treatment expectations and access.
Clinicians, researchers, newly diagnosed IBD patients, and patients on or considering biologic therapy
The analysis used the IQVIA Disease Analyzer to identify 10,009 patients aged 15–80 with newly diagnosed Crohn’s disease or ulcerative colitis and at least one prescription within 12 months of diagnosis. Mesalazine remained the dominant therapy for UC, while biologics became substantially more common in CD in the later period.
Thiopurine prescriptions declined over time. Prescription patterns also varied by age and differed between CD and UC.
Observational database studies show patterns and associations but cannot prove that newer drugs are better; national practice, reimbursement, and guideline changes can drive prescribing trends.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Early-phase trials test whether new treatments are safe and show biological activity. This study measures fecal calprotectin, a biomarker of intestinal inflammation, so it could provide early signals about whether ND-12...
People with IBD and their clinicians need to know whether common IBD treatments change COVID-19 risk or should be stopped. This review provides practical recommendations (continue most maintenance drugs; avoid systemic...
ILD is a potentially serious extraintestinal complication that appears more often with ulcerative colitis than with Crohn’s disease in this cohort study. Patients with both IBD and ILD had higher healthcare use and...
